Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

NCT05445765 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed and/or Refractory Acute Myeloid Leukemia
High Risk Hematologic Malignancies

Interventions

BIOLOGICAL: anti-CD33 CAR T cells

Sponsor

iCell Gene Therapeutics

Collaborators

[object Object]